Commercialization of neoantigen dendritic-cell vaccine therapy
First written in FY2016. 14 of 19 entries say "Restated". Latest entry: FY2023-Q3.
No other company in this theme has enough history to compare yet.
- FY2023-Q3RestatedAnnual report
「We are jointly conducting research and development of cancer treatments using dendritic cell therapy with the DC Vaccine Consortium, an association of dendritic cell immunotherapy comprising 3 medical corporations based in Osaka, Fukuoka, and Tokyo (Medical Corporation Kyoshinkai, Osaka Cancer Immuno-Chemotherapy Clinic; Medical Corporation Jiseikai, Fukuoka Cancer Center Clinic; and Medical Corporation Biocerakai, Biocera Clinic), by granting the consortium a non-exclusive license to the peptide vaccine for which we hold the license.」
The company continues to grant a license to the DC Vaccine Consortium, comprising 3 medical corporations, and conduct joint research. - FY2023-Q1RestatedAnnual report
「We are jointly conducting research and development of cancer treatments using dendritic cell therapy with the DC Vaccine Consortium, an association of dendritic cell immunotherapy comprising 3 medical corporations based in Osaka, Fukuoka, and Tokyo (Medical Corporation Kyoshinkai, Osaka Cancer Immuno-Chemotherapy Clinic; Medical Corporation Jiseikai, Fukuoka Cancer Center Clinic; and Medical Corporation Biocerakai, Biocera Clinic), by granting the consortium a non-exclusive license to the peptide vaccine for which we hold the license.」
The company continues to grant a license to the DC Vaccine Consortium, comprising 3 medical corporations, and conduct joint research. - FY2022-Q3RestatedAnnual report
「We are jointly conducting research and development of cancer treatments using dendritic cell therapy with the DC Vaccine Consortium, an association of dendritic cell immunotherapy comprising 3 medical corporations based in Osaka, Fukuoka, and Tokyo (Medical Corporation Kyoshinkai, Osaka Cancer Immuno-Chemotherapy Clinic; Medical Corporation Jiseikai, Fukuoka Cancer Center Clinic; and Medical Corporation Biocerakai, Biocera Clinic), by granting the consortium a non-exclusive license to the peptide vaccine for which we hold the license.」
The company continues to grant a license to the DC Vaccine Consortium, comprising 3 medical corporations, and conduct joint research. - FY2022-Q1RestatedAnnual report
「We are jointly conducting research and development of cancer treatments using dendritic cell therapy with the DC Vaccine Consortium, an association of dendritic cell immunotherapy comprising 3 medical corporations based in Osaka, Fukuoka, and Tokyo (Medical Corporation Kyoshinkai, Osaka Cancer Immuno-Chemotherapy Clinic; Medical Corporation Jiseikai, Fukuoka Cancer Center Clinic; and Medical Corporation Biocerakai, Biocera Clinic), by granting the consortium a non-exclusive license to the peptide vaccine for which we hold the license.」
The company continues to grant a license to the DC Vaccine Consortium, comprising 3 medical corporations, and conduct joint research. - FY2021-Q3RestatedAnnual report
「We are jointly conducting research and development of cancer treatments using dendritic cell therapy with the DC Vaccine Consortium, an association of dendritic cell immunotherapy comprising 3 medical corporations based in Osaka, Fukuoka, and Tokyo (Medical Corporation Kyoshinkai, Osaka Cancer Immuno-Chemotherapy Clinic; Medical Corporation Jiseikai, Fukuoka Cancer Center Clinic; and Medical Corporation Biocerakai, Biocera Clinic), by granting the consortium a non-exclusive license to the peptide vaccine for which we hold the license.」
The company continues to grant a license to the DC Vaccine Consortium, comprising 3 medical corporations, and conduct joint research. - FY2021-Q2RestatedAnnual report
「We are jointly conducting research and development of cancer treatments using dendritic cell therapy with the DC Vaccine Consortium, an association of dendritic cell immunotherapy comprising 3 medical corporations based in Osaka, Fukuoka, and Tokyo (Medical Corporation Kyoshinkai, Osaka Cancer Immuno-Chemotherapy Clinic; Medical Corporation Jiseikai, Fukuoka Cancer Center Clinic; and Medical Corporation Biocerakai, Biocera Clinic), by granting the consortium a non-exclusive license to the peptide vaccine for which we hold the license.」
The company continues to grant a license to the DC Vaccine Consortium, comprising 3 medical corporations, and conduct joint research. - FY2021-Q1RestatedAnnual report
「We are jointly conducting research and development of cancer treatments using dendritic cell therapy with the DC Vaccine Consortium, an association of dendritic cell immunotherapy comprising 3 medical corporations based in Osaka, Fukuoka, and Tokyo (Medical Corporation Kyoshinkai, Osaka Cancer Immuno-Chemotherapy Clinic; Medical Corporation Jiseikai, Fukuoka Cancer Center Clinic; and Medical Corporation Biocerakai, Biocera Clinic), by granting the consortium a non-exclusive license to the peptide vaccine for which we hold the license.」
The company continues to grant a license to the DC Vaccine Consortium, comprising 3 medical corporations, and conduct joint research. - FY2020-Q3RestatedAnnual report
「We are jointly conducting research and development of cancer treatments using dendritic cell therapy with the DC Vaccine Consortium, an association of dendritic cell immunotherapy comprising 3 medical corporations based in Osaka, Fukuoka, and Tokyo (Medical Corporation Kyoshinkai, Osaka Cancer Immuno-Chemotherapy Clinic; Medical Corporation Jiseikai, Fukuoka Cancer Center Clinic; and Medical Corporation Biocerakai, Biocera Clinic), by granting the consortium a non-exclusive license to the peptide vaccine for which we hold the license.」
The company continues to grant a license to the DC Vaccine Consortium, comprising 3 medical corporations, and conduct joint research. - FY2020-Q2RestatedAnnual report
「We believe that this will play a major role in immunotherapies using oncoantigens and neoantigens in the implementation of precision medicine in the clinical cancer field supported by the company and CPM.」
The company continues the grant of licenses to the DC Vaccine Consortium and joint research as a framework for immunotherapy in personalized medicine. - FY2020-Q1RestatedAnnual report
「CPM also conducts research into new personalized cancer immunotherapies, including neoantigen dendritic cell therapy and TCR gene-transduced T-cell therapy.」
The company continues research into personalized immunotherapies, including neoantigen dendritic cell therapy and TCR gene-transduced T-cell therapy. - FY2019-Q1RaisedAnnual report
「CPM also conducts research into new personalized immunotherapies, including neoantigen dendritic cell therapy and TCR gene-transduced T-cell therapy.」
The scope of research into personalized immunotherapies has expanded, with TCR gene-transduced T-cell therapy explicitly added to the existing neoantigen dendritic cell therapy. - FY2018RestatedAnnual report
「We are jointly conducting research and development of treatments using dendritic cell therapy with the DC Vaccine Consortium, an association of dendritic cell immunotherapy comprising 3 medical corporations based in Osaka, Fukuoka, and Tokyo (Medical Corporation Kyoshinkai, Osaka Cancer Immuno-Chemotherapy Clinic; Medical Corporation Jiseikai, Fukuoka Cancer Center Clinic; and Medical Corporation Biocerakai, Biocera Clinic), by granting the consortium a non-exclusive license to the peptide vaccine for which we hold the license.」
The company continues to grant a non-exclusive license to the DC Vaccine Consortium, comprising 3 medical corporations, and conduct joint research. - FY2018-Q3RestatedAnnual report
「We are jointly conducting research and development of treatments using dendritic cell therapy with the DC Vaccine Consortium, an association of dendritic cell immunotherapy comprising 3 medical corporations based in Osaka, Fukuoka, and Tokyo (Medical Corporation Kyoshinkai, Osaka Cancer Immuno-Chemotherapy Clinic; Medical Corporation Jiseikai, Fukuoka Cancer Center Clinic; and Medical Corporation Biocerakai, Biocera Clinic), by granting the consortium a non-exclusive license to the peptide vaccine for which we hold the license.」
The company continues to grant a non-exclusive license to the DC Vaccine Consortium, comprising 3 medical corporations, and conduct joint research. - FY2018-Q2AdvancedAnnual report
「We are jointly conducting research and development of treatments using dendritic cell therapy with the DC Vaccine Consortium, an association of dendritic cell immunotherapy comprising 3 medical corporations based in Osaka, Fukuoka, and Tokyo (Medical Corporation Kyoshinkai, Osaka Cancer Immuno-Chemotherapy Clinic; Medical Corporation Jiseikai, Fukuoka Cancer Center Clinic; and Medical Corporation Biocerakai, Biocera Clinic), by granting the consortium a non-exclusive license to the peptide vaccine for which we hold the license.」
The grant of a non-exclusive license to the DC Vaccine Consortium, comprising 3 medical corporations, and the joint research have advanced from the agreement stage to the launch and implementation stage. - FY2018-Q1ReframedAnnual report
「As of the date of submission of this document, we had agreed with the DC Vaccine Consortium, an association of dendritic cell immunotherapy comprising 3 medical corporations based in Osaka, Fukuoka, and Tokyo (Medical Corporation Kyoshinkai, Osaka Cancer Immuno-Chemotherapy Clinic; Medical Corporation Jiseikai, Fukuoka Cancer Center Clinic; and Medical Corporation Biocerakai, Biocera Clinic), to grant the consortium a non-exclusive license to the peptide vaccine for which we hold the license and jointly conduct research and development of treatments using dendritic cell therapy. We believe that this joint research will play a major role in immunotherapies using oncoantigens and neoantigens in the implementation of personalized medicine in the clinical cancer field supported by the company and its subsidiary CPM.」
Separate from the plan with テラ社, which disappeared from the prior year's disclosure, a new framework was presented involving the grant of a non-exclusive license to the DC Vaccine Consortium, comprising 3 medical corporations, and joint research. Its relationship with oncoantigen and neoantigen immunotherapies in personalized medicine supported by CPM was also made clear. - FY2017DroppedAnnual reportThe annual securities report contains no reference, under Business Activities or Research and Development Activities, to the commercialization of neoantigen dendritic cell vaccine therapy with テラ社.
- FY2017-Q2RestatedAnnual report
「We had agreed with テラ社 to work jointly on the commercialization of neoantigen dendritic cell vaccine therapy based on the analysis of genetic abnormalities in cancer cells.」
The company continues to pursue a plan to commercialize neoantigen dendritic cell vaccine therapy jointly with テラ社. - FY2017-Q1RestatedAnnual report
「We had agreed with テラ社 to work jointly on the commercialization of neoantigen dendritic cell vaccine therapy based on the analysis of genetic abnormalities in cancer cells.」
The company continues to pursue a plan to commercialize customized vaccine therapy jointly with テラ社. - FY2016First statedAnnual report
「As of the date of submission of this document, we had agreed with テラ社 to work jointly on the commercialization of neoantigen dendritic cell vaccine therapy based on the analysis of genetic abnormalities in cancer cells.」
A plan to develop a joint business with テラ株式会社 involving customized vaccines based on each patient's genetic abnormalities.